← All trials
NCT01033760
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2010
- Primary completion
- Jul 1, 2013
- Completion date
- Dec 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- French National Agency for Research on AIDS and Viral HepatitisLead sponsor
- Conception Hospital, MarseilleOverall official - principal investigator
- Gilead SciencesCollaborator
- PfizerCollaborator
- MerckCollaborator
- Johnson and JohnsonCollaborator
- Institut PasteurOverall official - principal investigator
- University of ParisOverall official - principal investigator
- Aix-University of MarseilleOverall official - principal investigator
- Centre Hospitalier de TourcoingOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.